Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Vitamins and Hormones|March 7, 2012
A new era for an ancient drug: arsenic trioxide and Hedgehog signalingElspeth M Beauchamp, Aykut UrenBlood|June 26, 2012
BH3 mimetics and multi-kinase inhibition in AMLElspeth M Beauchamp, Leonidas C PlataniasPlos One|May 12, 2011
YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasionSaid Rahim, Elspeth M Beauchamp, Yali Kong, et al.Scientific Reports|September 8, 2019
Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastomaFrank Eckerdt, Jessica Clymer, Jonathan B Bell, et al.Oncotarget|April 1, 2015
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinaseMarco Colamonici, Gavin Blyth, Diana Saleiro, et al.Molecular Cancer Therapeutics|October 26, 2014
Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursorsElspeth M Beauchamp, Ewa M Kosciuczuk, Ruth Serrano, et al.Oncotarget|September 17, 2015
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemiasDany A Curi, Elspeth M Beauchamp, Gavin T Blyth, et al.Chemical Biology & Drug Design|July 2, 2019
Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screeningRama K Mishra, Matthew R Clutter, Gavin T Blyth, et al.Blood Cancer Journal|March 4, 2021
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemiaBartholomew J Eisfelder, Caner Saygin, Joseph Wynne, et al.Blood Neoplasia|June 24, 2025
Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AMLSara H Small, Ricardo E Perez, Elspeth M Beauchamp, et al.Pageof 4